investors & media

More events are coming soon.

corporate profile

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.

With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

stock quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

press releases

5/29/2024

SOMERVILLE, Mass. --(BUSINESS WIRE)--May 29, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that O. James Sterling , has been appointed chief financial officer (CFO), effective June 10, 2024 . Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics

Read more
5/9/2024

- First patient start (cell collection) for LYFGENIA completed – - 15 patient starts to date in 2024 (11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA); 85 to 105 patient starts anticipated across the portfolio in 2024 - - First quarter 2024 net revenue of $18.6 million - - Management to host conference call

Read more
5/6/2024

SOMERVILLE, Mass. --(BUSINESS WIRE)--May 6, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9 , at 8:00 a.m. ET . To participate in the conference call, please dial +1 (800) 715-9871 (

Read more